Business Wire

MURATA-MANUFACTURING

14.5.2024 05:01:33 CEST | Business Wire | Press release

Share
Murata’s New LCT Redefines Power Supply Noise Suppression, Reducing Component Count and Costs

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) unveils a significant advancement in the realm of electronic components with the launch of its innovative L Cancel Transformer (LCT). This remarkable product is the first of its kind and can neutralize the equivalent series inductance (ESL) of a capacitor, optimizing its noise-reducing capabilities. Utilizing Murata’s exclusive ceramic multilayer technology, this breakthrough solution allows engineers to reduce system noise while decreasing costs and component count.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513693449/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

[Murata Manufacturing Co., Ltd.] L Cancel Transformer(Photo: Business Wire)

As the demand for miniaturized and highly functional electronics increases, the issue of electromagnetic noise is becoming increasingly prominent for many industries. As a noise countermeasure, capacitors are often utilized between the power supply line and ground, but this method is not without its challenges. The noise removal effectiveness of the capacitor is optimal when a capacitor’s impedance is lowest. However, capacitor impedance can rise due to its ESL, particularly at frequencies beyond the self-resonant frequency, undermining the efficacy of the noise cancellation. To minimize this impact, it is common practice to connect numerous capacitors in parallel in order to collectively reduce impedance, at the expense of Bill of Material (BoM) component count and costs.

Murata’s LCT is a revolutionary new concept capable of resolving the longstanding challenge of managing power supply noise and capacitor component count. Murata’s LCT component is specifically engineered to minimize noise within the frequency range of a few MHz to 1GHz. It achieves this by utilizing negative mutual inductance to reduce a noise-reducing capacitor’s ESL and therefore increase the effectiveness of its operation, drastically reducing the number of required capacitors.

By using non-magnetic ceramic multilayer technology in its construction, the LCT ensures stable negative inductance and low DC resistance (maximum 55mΩ) even in the presence of current variations and is suitable for a wide range of applications, including consumer, industrial and healthcare products. Murata’s LCT breakthrough is a result of their extensive multilayer ceramic knowledge and redefines power supply noise reduction circuit design, and minimizes a significant and persistent electronic design challenge.

Each LCT is suitable for temperatures up to temperatures 125oC and since there is no DC superposition characteristic, it can be used with stable negative inductance up to 3A. The surface mount device (SMD) measures just 2.0 x 1.25 x 0.95 mm and is available in tape and reel packing.

“Murata’s new LCT is a true innovation that does not merely improve what is available, but redefines what is seen as a standard noise suppression component by radically redefining the entire concept”, said Masamichi Ando, Vice President Business Incubation Center Corporate Technology & Business Development Unit, at Murata. “With this revolutionary component, engineers will be able to reduce component count, system complexity and costs, helping to both further miniaturize their solutions and reduce its impact on the environment by lowering material consumption.”

Murata’s LCT (Part number: LXLC21HN0N9C0L) is entering production with samples available now. For more information please visit here.

Please contact us for details: contact form

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513693449/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye